Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CSP #596 - Optimal Treatment for Recurrent Clostridium Difficile Infection

NCT02667418 is registered in ClinicalTrials.gov with VA Office of Research and Development as lead sponsor.

NCT NCT02667418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02667418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CSP #596 - Optimal Treatment for Recurrent Clostridium Difficile Infection
Lead sponsor
VA Office of Research and Development
Phase
Phase 4
Overall status
Terminated
Start date
February 19, 2016
Completion date
August 31, 2024
Enrollment
308 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

clostridium, difficile, fidaxomicin, vancomycin